RE:RE:NASDAQ Uplisting: Avalyn raised C$80 million going into its inhaled Phase I fibrosis clinical trial. Dr. Ask and Dr. Kolb of McMaster both worked with that company and have both expressed their excitement about CZO's program with Dr. Kolb saying CZO could profoundly alter the landscape if results in mice are replicated in humans. COVID fibrosis wasn't around when Avalyn raised the C$80 million and CZO's treatment can also work on fibrosis outside the lung. Over 40% of deaths worldwide are attributable to fibrosis Dr. Ask noted. CZO's delivery technology can also work for other drugs other than for fibrosis.
CZO could also have a PGX deal for CoQ10. Talks are underway with serious companies right now and they understand the unique selling point of bioavailability CZO has demonstrated. CZO blew away the gold standard in its bioavailability study. CoQ10 is an established $4 billion market. CZO's technology may be hijacking macrophages, using macrophages as a Trojan Horse. The technology is being used to investigate the delivery of other drugs it has been previously noted.
Gilles also noted, as an example, Symrise could be interested in a CoQ10 PGX cream as a second generation Aveeno.
Yeast beta glucan is an established $1 billion market and CZO's PGX-YBG has been found multi-fold more immune stimulatory. A fraction of the dose may be required to obtain the same effect.
CZO also believes it has a wound healing franchise given recent results and studies at McMaster.
The avenanthramide clinical trial is also expected to commence enrollment this month with Phase I completed by the end of the year. Gilles has noted the non-steroidal anti-inflammatory market is worth of $60 billion per year.